Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eide

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Molecular Vision|October 17, 2017
Multicellular tumor spheroids of human uveal melanoma induce genes associated with anoikis resistance, lipogenesis, and SSXsCharlotte Ness, Øystein Garred, Nils A Eide, et al.
Science Signaling|July 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminibSerena Muratcioglu, Christopher A Eide, Chien-Lun Hung, et al.
Cancer Research|July 18, 2019
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein DegradationGeorge M Burslem, Anna Reister Schultz, Daniel P Bondeson, et al.
Blood|June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsHeather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
BMJ Open|June 18, 2026
Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK studyIngrid Charlotte Kongerud, Karsten Midtvedt, Marit D Solbu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
BMC Cancer|February 10, 2016
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypesHanne A Eide, Ann Rita Halvorsen, Maria Moksnes Bjaanæs, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Distinct patterns of osteoradionecrosis after photon-based radiotherapy and carbon ion radiotherapy for unresectable adenoid cystic carcinoma of the head and neck: case series from two institutionsEivind Storaas, Marta D Switlyk, Sigrun Dahl, et al.
British Journal of Haematology|October 20, 2022
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemiaEvan J Barnes, Christopher A Eide, Andy Kaempf, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 12, 2015
The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantationIvar A Eide, Trond Jenssen, Anders Hartmann, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Molecular Vision|October 17, 2017
Multicellular tumor spheroids of human uveal melanoma induce genes associated with anoikis resistance, lipogenesis, and SSXsCharlotte Ness, Øystein Garred, Nils A Eide, et al.
Science Signaling|July 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminibSerena Muratcioglu, Christopher A Eide, Chien-Lun Hung, et al.
Cancer Research|July 18, 2019
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein DegradationGeorge M Burslem, Anna Reister Schultz, Daniel P Bondeson, et al.
Blood|June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsHeather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
BMJ Open|June 18, 2026
Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK studyIngrid Charlotte Kongerud, Karsten Midtvedt, Marit D Solbu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
BMC Cancer|February 10, 2016
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypesHanne A Eide, Ann Rita Halvorsen, Maria Moksnes Bjaanæs, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Distinct patterns of osteoradionecrosis after photon-based radiotherapy and carbon ion radiotherapy for unresectable adenoid cystic carcinoma of the head and neck: case series from two institutionsEivind Storaas, Marta D Switlyk, Sigrun Dahl, et al.
British Journal of Haematology|October 20, 2022
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemiaEvan J Barnes, Christopher A Eide, Andy Kaempf, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 12, 2015
The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantationIvar A Eide, Trond Jenssen, Anders Hartmann, et al.
Pageof 12